Interferons: Unapproved uses, dosages, or indications

Clinics in Dermatology

Volumn 20, Issue 5, 2002, Pages 493-504

  Orion, Edith ^a   Matz, Hagit ^a   Wolf, Ronni ^a  

^a KAPLAN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANESTHETIC AGENT; AZATHIOPRINE; BETA INTERFERON; CHLORAMBUCIL; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; DAPSONE; GAMMA INTERFERON; IMMUNOGLOBULIN E; INTERFERON; INTERLEUKIN 4; PLACEBO; THALIDOMIDE;

ACTINIC KERATOSIS; ATOPIC DERMATITIS; BASAL CELL CARCINOMA; BEHCET DISEASE; CHILL; CHROMOSOME 6; CHRONIC GRANULOMATOUS DISEASE; CHRONIC HEPATITIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; DERMATOLOGY; DISCOID LUPUS ERYTHEMATOSUS; FEVER; FOLLICULAR LYMPHOMA; HAIRY CELL LEUKEMIA; HEMANGIOMA; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS; HISTOLOGY; HUMAN; IMMUNOTHERAPY; KAPOSI SARCOMA; KELOID; KERATOACANTHOMA; KIDNEY CARCINOMA; MELANOMA; MULTIPLE SCLEROSIS; NEUTROPENIA; OSTEOPOROSIS; PORPHYRIA CUTANEA TARDA; PRIORITY JOURNAL; PSORIASIS; REVIEW; SCAR; SCLERODERMA; SIDE EFFECT; SKIN LUPUS ERYTHEMATOSUS; SKIN LYMPHOMA; SPASTICITY; SQUAMOUS CELL CARCINOMA; VARICELLA ZOSTER VIRUS; VASCULITIS; VERRUCA VULGARIS; VIRUS; WART VIRUS;

EID: 0036757828     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(02)00274-2     Document Type: Article

References (157)

1. Stadler R. Interferons in dermatology present-day standards . Dermatol Ther. 16:1998;377-398.
2. Balkwill F.R. Interferons. Lancet. 1:1989;1060-1063.
3. Streuli M., Nagata S., Weissman C. At least three human type interferons structure of two . Science. 209:1980;1343-1346.
4. Stadler R., Ruszczak Z. Interferons new additions and indications for use . Dermatol Clin. 11:1993;187-199.
5. th anniversary of the discovery of interferons . Cancer Res. 58:1998;7489-7499.
6. Berman B., Sequeira M. Dermatologic uses of interferons. Dermatol Clin. 13:1995;699-711.
7. Cada D.J., Covington T.R., Drug facts and comparisons. 2000;1571-1580 Facts and Comparisons, Inc, St. Louis, MO.
8. Lung H.Z. How often does squamous cell carcinoma of the skin metastasize? Arch Dermatol. 92:1965;635-637.
9. Moller R., Reymann F., Hou-Jensen K. Metastases in dermatological patients with squamous cell carcinoma. Arch Dermatol. 115:1979;703-705.
10. Marks R. Solar keratoses. Br J Dermatol. 122:(suppl 35):1990;49.
11. Ghadially F.N. The role of hair follicle in origin and evolution of some cutaneous neoplasms in man and experimental animals. Cancer. 14:1961;801.
12. Edwards L., Berman B., Rapini R.P., et al. Treatment of cutaneous squamous cell carcinomas by intralesional interferon-α2b therapy. Arch Dermatol. 128:1992;1486-1489.
13. Edwards L., Levine N., Weidner M., et al. Effects of intralesional α2-interferon on actinic keratoses. Arch Dermatol. 122:1986;779-782.
14. Edwards L., Levine N., Smiles K.A. The effect of topical interferon-α2b on actinic keratoses. J Dermatol Surg Oncol. 16:1990;446-449.
15. Kowalzick L., Mensing H., Weyer U., et al. Bowenoid actinic keratosis therapy with intralesional injections of recombinant β-interferon . Hautarzt. 43:1992;373-375.
16. Wickramasinghe L., Hindson T.C., Wacks H. Treatment of neoplastic skin lesions with intralesional interferon. J Am Acad Dermatol. 20:1989;71-74.
17. Grob J.J., Suzini F., Richard A., et al. Large keratoacanthomas treated with intralesional interferon-α2a. J Am Acad Dermatol. 29:1993;237-241.
18. Eichenfeld L.F., Lucky A.W., Boguniewicz M., et al. Safety and efficacy of Pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 46:2002;495-504.
19. Hanifin J.M., Chan S. Biochemical and immunologic mechanisms in atopic dermatitis new targets for emerging therapies . J Am Acad Dermatol. 41:1999;72-77.
20. Leung D.Y.M. Atopic dermatitis new insights and opportunities for therapeutic intervention . J Allergy Clin Immunol. 105:2000;860-876.
21. Pene J., Russet F., Briere F., et al. IgE production by normal human B cells induced by alloreactive T cell clones is mediated by IL-4 and suppressed by IFN-γ J Immunol. 141:1988;1218-1224.
22. Leung D.Y., Hanifin J.M., Charlesworth E.N., et al. Disease management of atopic dermatitis a practice parameter: joint task force on practice parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the joint council of Allergy, Asthma and Immunology: work group on atopic dermatitis . Ann Allergy Asthma Immunol. 79:1997;197-211.
23. Cooper K.D. New therapeutic approaches in atopic dermatitis. Clin Rev Allergy. 11:1993;543-559.
24. De Prost Y. Atopic dermatitis recent therapeutic advances . Pediatr Dermatol. 9:1992;386-389.
25. Reinhold U., Wehrmann W., Kukel S., Kreysler H.W. Evidence that defective interferon-γ production in atopic dermatitis patients is due to intrinsic abnormalities. Clin Exp Immunol. 79:1990;374-379.
26. Reinhold U., Wehrmann W., Kukel S., Kreysler H.W. Recombinant interferon γ in atopic dermatitis. Lancet. 1:1990;1282.
27. Hanifin J.M., Schneider L.C., Leung D.Y.M., et al. Recombinant interferon γ therapy for atopic dermatitis. J Am Acad Dermatol. 28:1993;189-197.
28. Block B., Taylor R.S., Gonzales A., et al. Peripheral blood leukocyte subsets in atopic dermatitis effects of γ interferon . J Invest Dermatol. 96:1991;604.
29. Sober A.J. Diagnosis and management of skin cancer. Cancer. 51:1983;2448.
30. Roenigk R.K., Ratz J.L., Bailin P.L., Wheeland R.G. Trends in the presentation and treatment of basal cell carcinomas. J Dermatol Surg Oncol. 12:1986;860-865.
31. Albright S.D. III. Treatment of skin cancer using multiple modalities. J Am Acad Dermatol. 7:1982;143-171.
32. Drake L.A., Ceilley R.I., Cornelison R.L., et al. Guidelines of care for basal cell carcinoma the American Academy of Dermatology Committee on guidelines of care . J Am Acad Dermatol. 26:1992;117-120.
33. Soler A.M., Warloe T., Berner A., Giercksky K.E. A follow-up study of recurrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-aminolaevulinate-based photodynamic therapy alone and with prior curettage. Br J Dermatol. 145:2001;467-471.
34. Greenway H.T., Cornell R.C., Tanner D.J., et al. Treatment of basal cell carcinoma with intralesional interferon. J Am Acad Dermatol. 15:1986;437-443.
35. Buechner S. Intralesional interferon-α2b in the treatment of basal cell carcinoma. J Am Acad Dermatol. 24:1991;731-734.
36. Stenquist B., Wennberg A.M., Gisslen H., Larko O. Treatment of aggressive basal cell carcinoma with intralesional interferon evaluation of efficacy by Mohs surgery . J Am Acad Dermatol. 27:1992;65-69.
37. Spiegel R. Additional indications for interferon therapy basal cell carcinoma, carcinoid, and chronic active hepatitis . Semin Oncol. 15:(suppl 5):1988;41-45.
38. Cornell R.C., Greenway H.T., Tucker S.B., et al. Intralesional interferon therapy for basal cell carcinoma. Arch Dermatol. 23:1990;694-700.
39. Lippman S.M., Shimm D.S., Meyskens F.L. Jr. Nonsurgical treatments for skin cancer retinoids and α-interferon . J Dermatol Surg Oncol. 14:1988;862-869.
40. Jorizzo J.L., Solomon A.R., Cavallo T. Behcet's syndrome immunopathologic and histopathologic assessment of pathergy lesions is useful in diagnosis and follow-up . Arch Pathol Lab Med. 109:1985;747-751.
41. Jorizzo J.L., Schmalstieg F.C., Solomon A.R. Jr, et al. Thalidomide effects in Behcet's syndrome and pustular vasculitis. Arch Intern Med. 146:1986;878-881.
42. Sharqui K. Suppression of Behcet's disease with dapsone. Br J Dermatol. 110:1984;493.
43. Yazici H., Pazarli H., Barnes C.G., et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med. 322:1990;281-285.
44. O'Duffy J.D., Robertson D.M., Goldstein N.P. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behcet's disease. Am J Med. 76:1984;75-84.
45. Nussenblatt R.B., Palestine A.G., Chan C.C., et al. Effectiveness of cyclosporin therapy for Behcet's disease. Arthritis Rheum. 28:1985;671-679.
46. Stubiger N., Kotter I., Deuter C., Zierhut M. Behcet's disease uveitis-therapy with interferon-α2a: prospective clinical study in 33 patients . Klin Monatsbl Augenheilkd. 218:2001;768-773.
47. Alpsoy E., Yilmaz E., Basaran E. Interferon therapy for Behcet's disease. J Am Acad Dermatol. 31:1994;617-619.
48. Mahrle G., Schultz H.J. Recombinant interferon-γ in dermatology. J Invest Dermatol. 95:1990;132s-137s.
49. Fierlbeck G., Rassner G. Rekombinantes interferon-γ bei psoriais arthropathica, progressive systemischer sklerodermie und morbus behcet. Med Klin. 83:1988;695-699.
50. Duvic M. Treatment of cutaneous T-cell lymphoma from a dermatologist's perspective. Clin Lymphoma. 1:(suppl 1):2000;s15-s20.
51. Bunn P.A., Foon K.A., Inde D.C., et al. Recombinant leukocyte A interferon an active agent in advanced cutaneous T-cell lymphomas . Ann Intern Med. 101:1984;484-487.
52. Smalley R.B., Borden E.C. Interferons current status and future directions of this prototypic biological . Semin Immunopathol. 2:1986;73-83.
53. Herberman R.B., Ortaldo J.R., Mantovani A., et al. Effects of human recombinant interferon on cytotoxic activity of natural killer cells and monocytes. Cell Immunol. 67:1982;160-167.
54. Schultz R.M. Macrophage activation by interferons. Lymphokine Rep. 1:1980;63-97.
55. Hoppe R.T., Medeiros L.J., Warnke R.A., Wood G.S. CD8+ tumor-infiltrating lymphocytes influence survival of patients with mycosis fungoides. J Am Acad Dermatol. 32:1995;448-453.
56. Gutterman J.U. Cytokine therapeutics lessons from interferon-α Proc Natl Acad Sci USA. 91:1994;1198-1205.
57. Olsen E.A., Rosen S.T., Vollmer R.T., et al. Interferon-α2a in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol. 20:1989;395-407.
58. Parronchi P., De Carli M., Manetti R., et al. IL-4 and IFN (α and γ) exert opposite regulatory effects on the development of cytotoxic potential by Th1 or Th2 human T-cell clones. J Immunol. 149:1992;2977-2983.
59. Apisarnthananarax N., Duvic M. Cutaneous T-cell lymphoma. Dermatol Clin. 19:2001;737-748.
60. Bunn P.A., Ihde D.C., Foon K.A. The role of recombinant interferon-α2a in the therapy of cutaneous T-cell lymphoma. Cancer. 57:(suppl 8):1986;1689-1695.
61. Vonderheid EC, Thompson R, Smiles KA, Lattanand A. Recombinant interferon-α2b in plaque-phase mycosis fungoides. Arch Dermatol 1087;123:757-63.
62. Wolff J.M., Zitelli J.A., Rabin B.S., et al. Intralesional interferon in the treatment of early mycosis fungoides. J Am Acad Dermatol. 13:1985;604-612.
63. Bunn P.A., Ihde D.C., Foon F.A. Recombinant interferon-α2a, an active agent in advanced cutaneous T-cell lymphoma. Int J Cancer. 1:1987;9-13.
64. Olsen E., Bunn P.A. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 9:1995;1089-1107.
65. VanderMolen L.A., Steis R.G., Duffey P.L., et al. Low versus high dose interferon-α2a in relapsed indolent non-Hodgkin lymphoma. J Natl Cancer Inst. 82:1990;235-238.
66. Jumbou O., N′guyen J.M., Tessier M.H., et al. Long-term follow up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-α Br J Dermatol. 140:1999;427-431.
67. Ross C., Tingsgaard P., Jorgensen H., Vejlsgaard G.L. Interferon treatment of cutaneous T-cell lymphoma. Eur J Haematol. 51:1993;63-72.
68. Vegna M.L., Papa G., Defazio D., et al. Interferon-α2a in cutaneous T-cell lymphoma. Eur J Haematol. 52:1990;32-85.
69. Kohn E.C., Steis R.G., Sausville E.A., et al. Phase II trial of intermittent high-dose recombinant interferon-α2a in mycosis fungoides and the Sézary syndrome. J Clin Oncol. 8:1990;155-160.
70. Nicolas J.F., Thiovelt J., Kanitakis J., Lyonnet S. Response of discoid and subacute cutaneous lupus erythematosus to recombinant interferon-α2a. J Invest Dermatol. 90:1990;142S-145S.
71. th ed. Andrew's diseases of the skin. 8:2000;172-204 WB Saunders Co, Philadelphia.
72. Knobler R.L. Systemic interferon therapy of multiple sclerosis the pros . Neurology. 38:1988;58-61.
73. Peddinani M.V., Savery F., Hang L.M. Human leukocyte interferon in the treatment of rheumatoid arthritis. Clin Ther. 9:1986;39-43.
74. Lever A.M.L., Brook M.G., Yap I., Thomas H.C. Treatment of thrombocytopenia with α interferon. Br Med J. 295:1987;1519-1520.
75. Proctor S.J., Jackson G., Carey P., Stark A. Short-course α-interferon therapy in severe unresponsive immune thrombocytopenic purpura. Lancet. 84:1988;380-392.
76. Thiovelt J., Nicolas J.F., Kanitakis J., et al. Recombinant interferon-α2a is effective in the treatment of discoid and subacute cutaneous lupus erythematosus. Br J Dermatol. 122:1990;405-409.
77. Jessop S., Whitelaw D., Jordaan F. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev. 1:2001;CD002954.
78. Martinez J., de Misa R.F., Torrelo A., Ledo A. Low-dose intralesional interferon α for discoid lupus erythematosus. J Am Acad Dermatol. 26:1992;494-496.
79. Shou-Nee S., Feng F.S., Wen Y.M., et al. Serum interferon in systemic lupus erythematosus. Br J Dermatol. 117:1987;155-159.
80. Kanayama Y., Kim T., Inariba H., et al. Possible involvement of interferon-αin the pathogenesis of fever in systemic lupus erythematosus. Ann Rheum Dis. 48:1989;861-863.
81. Thornton C.M., Lawrence E.F. Treatment of common cutaneous vascular disorders of childhood. Dermatologic therapy. City, State/Country. 1997;68-77 Munksgeerd International Publishers.
82. Enjolras O., Riche M.C., Merland J.J., Escande J.P. Management of alarming hemangiomas in infancy a review of 25 cases . Pediatrics. 85:1990;491-498.
83. Turner C., Gross S. Treatment of recurrent suprahyoid cervicofacial lymphangioma with intravenous cyclophosphamide. Am J Pediatr Hematol Oncol. 16:1994;325-328.
84. Morad A.B., McClain K.L., Ogden A.K. The role of tranexamic acid in the treatment of giant hemangiomas in newborns. Am J Pediatr Hematol Oncol. 15:1993;383-385.
85. De Prost Y., Teillac D., Bedemer C., et al. Successful treatment of Kasabach-Merritt syndrome with pentoxifylline. J Am Acad Dermatol. 25:1991;854-855.
86. Kohout M.P., Hansen L.A., Pribaz J.J., Mulliken J.B. Arteriovenous malformations of the head and neck natural history and management . Plast Reconstr Surg. 102:1998;643-654.
87. Lundell M., Furst C.J., Hedlund B., Holm L.E. Radium treatment for hemangioma in early childhood reconstruction and dosimetry of treatments, 1920-1959 . Acta Oncol. 29:1990;551-556.
88. Bassukas I.D., Abuzahra F., Hundeiker M. Regression phase as therapeutic goal of cryosurgical treatment of growing capillary infantile hemangiomas treatment decisions, treatment strategy and results of an open clinical study . Hautarzt. 51:2000;231-238.
89. Staindl O. Treatment of hemangiomas of the face with magnesium seeds. Arch Otorhinolaryngol. 246:1989;213-217.
90. Achauer B.M., Chang C.J., Vander-Kam V.M. Management of hemangioma of infancy review of 245 patients . Plast Reconstr Surg. 99:1997;1301-1308.
91. Lin X.X., Wang W., Wu S.F., et al. Treatment of capillary vascular malformation (port-wine stains) with photochemotherapy. Plast Reconstr Surg. 99:1997;1826-1830.
92. Komiyama M., Nakajima H., Kitano S., et al. Endovascular treatment of huge cervicofacial hemangioma complicated by Kasabach-Merritt syndrome. Pediatr Neurosurg. 33:2000;26-30.
93. Breviere G.M., Bonnevalle M., Pruvo J.P., et al. Use of Ethibloc in the treatment of cystic and venous angiomas in children 19 cases . Eur J Pediatr Surg. 3:1993;166-170.
94. Stringel G., Dastous J. Klippel-Trenaunay syndrome and other cases of lower limb hypertrophy pediatric surgical implications . J Pediatr Surg. 22:1987;645-650.
95. Bielenberg D.R., Bucana C.D., Sanchez R., et al. Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, IFN-β Int J Oncol. 14:1999;401-408.
96. Ezekowitz R.A.B., Mulliken J.B., Folkman J. Interferon-α2a therapy for life-threatening hemangiomas of infancy. N Engl J Med. 326:1992;1456-1463.
97. Correction to Interferon-α2a therapy for life-threatening hemangiomas of infancy . N Engl J Med. 330:1994;300.
98. Additional corrections Interferon for hemangiomas of infancy . N Engl J Med. 333:1995;595-596.
99. Tamayo L., Ortiz D.M., Orozco-Covarrubias L., et al. Therapeutic efficacy of interferon-α2b in infants with life-threatening giant hemangiomas. Arch Dermatol. 133:1997;1567-1571.
100. Enjolras O., Mulliken J.B. Vascular tumors and vascular malformations (new issues). Adv Dermatol. 13:1998;375-423.
101. Rampini E., Rampini P., Occella C., Bleidl D. Interferon-α2b for treatment of complex cutaneous haemangiomas of infancy a reduced dosage schedule . Br J Dermatol. 142:2000;189-191.
102. Dubois J., Hershon L., Carmant L., et al. Toxicity profile of interferon-α2b in children a prospective evaluation . J Pediatr. 135:1999;782-785.
103. Barlow C.F., Priebe C.J., Mulliken J.B., et al. Spastic diplegia as a complication of interferon-α2a treatment of hemangiomas in infancy. J Pediatr. 132:1998;527-530.
104. Anger J., Carneiro R.G., Pinus J., et al. The rebound effect in the treatment of complex hemangioma with interferon-α2a. Rev Paul Med. 116:1998;1826-1828.
105. Tredget E.E., Nedelec B., Scott P.G., Ghahary A. Hypertrophic scars, keloids and contractures the cellular and molecular basis for therapy . Surg Clin North Am. 77:1997;701-730.
106. Berman B., Flores F. The treatment of hypertrophic scars and keloids. Eur J Dermatol. 8:1998;591-595.
107. Jimenez S.A., Freundlich B., Rosenbloom J. Selective inhibition of human diploid fibroblast collagen synthesis by interferons. J Clin Invest. 74:1984;1112-1116.
108. Ghahary A., Shen Y.J., Scott P.G., Tredget E.E. Expression of fibronectin messenger RNA in hypertrophic and normal dermal tissues and in vitro regulation by interferon-α2b. Wound Repair Regen. 1:1993;166-174.
109. Harrop A.R., Ghahary A., Scott P.G., et al. Regulation of collagen synthesis and mRNA expression in normal and hypertrophic scar fibroblasts in vitro by interferon-γ J Surg Res. 58:1995;471-477.
110. Harrop A.R., Ghahary A., Scott P.G., et al. Regulation of collagen synthesis and messenger RNA levels in normal and hypertrophic scar fibroblasts in vitro by interferon-γ J Surg Res. 58:1995;471-477.
111. Ghahary A., Shen Y.J., Nedelec B., et al. Interferons-γ and α2b differentially regulate the expression of collagenase and tissue inhibitor of metalloproteinase-1 messenger RNA in human hypertrophic and normal dermal fibroblasts. Wound Repair Regen. 3:1995;176-184.
112. Dans M.J., Isseroff R. Inhibition of collagen lattice contraction by pentoxifylline and interferon-α, β, and γ J Invest Dermatol. 102:1994;118-121.
113. Nedelec B., Shen Y.J., Ghahary A., et al. The effect of interferon-α2b on the expression of cytoskeletal proteins in an in vitro model of wound contraction. J Lab Clin Med. 126:1995;474-484.
114. Sahara K., Kucukcelebi A., Ko F., et al. Suppression of in vitro proliferative scar fibroblast contraction by interferon-α2b. Wound Repair Regen. 1:1993;22-27.
115. Berman B., Duncan M.R. Short-term keloid treatment in vivo with human interferon-α2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan and collagenase production in vitro. J Am Acad Dermatol. 21:1989;694-702.
116. Granstein R.D., Rook A., Flotte T.J., et al. A controlled trial of intralesional recombinant interferon-γ in the treatment of keloidal scarring. Arch Dermatol. 126:1990;1295-1302.
117. Darbi I., Skalli O., Gabbiani G. α-Smooth muscle actin is transiently expressed by myofibroblasts during experimental wound healing. Lab Invest. 63:1990;21-29.
118. Desmouliere A., Redard M., Darby I., Gabbiani G. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol. 146:1995;56-66.
119. Nedelec B., Shankowsky H., Scott P.G., et al. Myofibroblasts and apoptosis in human hypertrophic scars the effect of interferon-α2b . Surgery. 130:2001;798-808.
120. Takeuchi M., Tredget E.E., Scott P.G., et al. The antifibrogenic effects of liposome-encapsulated IFN-α2b cream on skin wounds. J Interferon Cytokine Res. 19:1999;1413-1419.
121. th ed. 1999;495-522 McGraw-Hill Publishers, New York.
122. Lebwohl M., Ali S. Treatment of psoriasis, part I topical therapy and phototherapy . J Am Acad Dermatol. 45:2001;467-498.
123. Lebwohl M., Ali S. Treatment of psoriasis, part II systemic therapy . J Am Acad Dermatol. 45:2001;649-661.
124. Morhenn V.B., Pregreson-Rodan K., Henzl-Mullen R., et al. Use of recombinant interferon-γ administered intramuscularly for the treatment of psoriais. Arch Dermatol. 123:1987;1633-1637.
125. Fierlbeck G., Rasner G. Interferon-γ in psoriatic arthritis. Dtsch Med Wochenschr. 111:1986;1313-1316.
126. Serpier H., Gillery P., Salmin-Her V., et al. Antagonistic effects of interferon-γ and interleukin-4 on fibroblasts cultures. J Invest Dermatol. 109:1997;158-162.
127. Kahan A., Amor B., Menkes C.J., Strauch G. Recombinant interferon-γ in the treatment of systemic sclerosis. Am J Med. 87:1989;273-277.
128. Mensing H. Therapy of progressive scleroderma with γ-interferon. Hautarzt. 42:1991;380-383.
129. Hein R., Behr J., Hundgen M., et al. Treatment of systemic sclerosis with γ-interferon. Br J Dermatol. 126:1992;496-501.
130. Freundlich B., Jimenez S.A., Steen V.D., et al. Treatment of systemic sclerosis with recombinant interferon γ a phase I/II clinical trial . Arthritis Rheum. 35:1992;1134-1142.
131. Vlachyiannopoulos P.G., Tsifetaki N., Dimitriou I., et al. Safety and efficacy of recombinant γ-interferon in the treatment of systemic sclerosis. Ann Rheum Dis. 55:1996;761-768.
132. Hunzelmann N., Anders S., Fierlbeck G. Systemic scleroderma multicenter trial of 1 year of treatment with recombinant interferon-γ rt al Arch Dermatol. 133:1997;609-613.
133. Polisson R.P., Gilkeson G.S., Pyun E.H., et al. A multicenter trial of recombinant human interferon-γ in patients with systemic sclerosis effects on cutaneous fibrosis and interleukin-2 receptor levels . J Rheumatol. 23:1996;654-658.
134. Grassegger A., Schuler G., Hessenberger G., et al. Interferon-γ in the treatment of systemic sclerosis a randomized controlled multicenter trial . Br J Dermatol. 139:1998;639-648.
135. Isaacs A., Lindenmann J. Virus interference, I the interferon . Proc R Soc Lond Ser B. 147:1957;258-267.
136. Gresser I. Biological effects of interferons. J Invest Dermatol. 95:1990;66s-71s.
137. Memar O.M., Tyring S.K. Antiviral agents in dermatology current status and future prospects . Int J Dermatol. 34:1995;597-606.
138. Cantell K. Development of antiviral therapy with α-interferons promises, false hopes and accomplishment . Ann Med. 27:1995;23028.
139. Pielop J., Wood A.C., Hsu S. Update on antiviral therapy for herpes simplex virus infection. Dermatol Ther. 13:2000;235-257.
140. Fleming D., McQuillan G., Johnson R.E., et al. Herpes simplex virus-2 in the United States 1976-1994. N Engl J Med. 16:1997;1105-1111.
141. Mendelson J., Clecner B.Y., Eiley S. Effects of recombinant interferon-α2 on clinical course of first episode genital herpes infection and subsequent recurrence. Genitourin Med. 62:1986;97-101.
142. Shupack J., Stiller M., Knobler E., et al. Topical α-interferon in recurrent genital herpes simplex infection a double-blind, placebo-controlled clinical trial . Dermatologica. 181:1990;134-138.
143. Friedman-Kien A.E., Klei R.J., Glase R.D., Czelusniack S.M. Treatment of recurrent genital herpes with topical α-interferon gel combined with nonoxynol-9. J Am Acad Dermatol. 15:1986;989-994.
144. Lebwohl M., Sacks S., Conant M., et al. Recombinant α-2 interferon gel treatment of recurrent herpes genitalis. Antiviral Res. 17:1992;235-243.
145. Sacks S.L., Varner T.L., Davies K.S., et al. Randomized, double-blind, placebo-controlled, patient-initiated study of topical high and low dose interferon-α with nonoxynol-9 in the treatment of recurrent genital herpes. J Infect Dis. 161:1990;692-698.
146. Batcheler L.M., Bonham D.C., Collins R., Liddell H.S. Topical interferon cream for the treatment of herpes genitalis a double-blind controlled trial . Aust N Z Obstet Gynaecol. 26:1986;239-241.
147. Glezerman M., Lunenfeld E., Cohen V., et al. Placebo-controlled trial of topical interferon in labial and genital herpes. Lancet. 1:1988;150-152.
148. Kuhls T.L., Sacher J., Pineda E., et al. Suppression of recurrent genital herpes simplex virus infection with recombinant-α2 interferon. J Infect Dis. 154:1986;437-442.
149. Carrasco D.A., Vander Straten M., Tyring S.K. Treatment of varicella-zoster virus and postherpetic neuralgia. Dermatol Ther. 13:2000;258-268.
150. Hope Simpson R.E. The nature of herpes zoster a long-term study and new hypothesis . Proc R Soc Lond B. 58:1965;9-20.
151. Weksler M.E. Immune senescence. Ann Neurol. 35:(suppl):1994;S35-S37.
152. Duschet P., Schwartz T., Soyer P., et al. Treatment of herpes zoster recombinant α-interferon versus acyclovir . Int J Dermatol. 27:1988;193-197.
153. De Villiers E.M. Papillomavirus and HPV typing. Clin Dermatol. 15:1997;199-206.
154. Berman B., Weinstein A. Treatment of warts. Dermatol Ther. 13:2000;290-304.
155. Vance J.C., Bart B.J., Hansen R.C., et al. Intralesional recombinant-α2a interferon for the treatment of patients with condyloma acuminatum or verruca plantaris. Arch Dermatol. 122:1986;272-277.
156. Nimura M. Intralesional human fibroblast interferon in common warts. J Dermatol. 10:1983;217-220.
157. Berman B., Davis-Reed L., Silverstein L., et al. Treatment of verrucae vulgaris with-α2 interferon. J Infect Dis. 154:1986;328-330.